Finch Therapeutics Group, Inc.
FNCH · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $107 | $861 | $18,532 |
| % Growth | -100% | -87.6% | -95.4% | – |
| Cost of Goods Sold | $174 | $1,520 | $5,507 | $57,279 |
| Gross Profit | -$174 | -$1,413 | -$4,646 | -$38,747 |
| % Margin | – | -1,320.6% | -539.6% | -209.1% |
| R&D Expenses | $0 | $7,199 | $52,863 | $57,279 |
| G&A Expenses | $0 | $26,910 | $38,088 | $21,238 |
| SG&A Expenses | $18,685 | $26,910 | $36,192 | $21,238 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$1,520 | $1,419 | $0 |
| Operating Expenses | $18,685 | $32,589 | $90,474 | $78,517 |
| Operating Income | -$18,859 | -$34,002 | -$95,120 | -$59,985 |
| % Margin | – | -31,777.6% | -11,047.6% | -323.7% |
| Other Income/Exp. Net | $4,982 | -$44,213 | -$19,526 | $1,825 |
| Pre-Tax Income | -$13,877 | -$78,215 | -$114,646 | -$58,160 |
| Tax Expense | $0 | -$3,461 | $0 | $0 |
| Net Income | -$13,877 | -$74,754 | -$114,646 | -$58,160 |
| % Margin | – | -69,863.6% | -13,315.4% | -313.8% |
| EPS | -8.64 | -46.59 | -72.12 | -36.72 |
| % Growth | 81.5% | 35.4% | -96.4% | – |
| EPS Diluted | -8.64 | -46.59 | -72.12 | -36.72 |
| Weighted Avg Shares Out | 1,606 | 1,605 | 1,590 | 1,584 |
| Weighted Avg Shares Out Dil | 1,606 | 1,605 | 1,590 | 1,584 |
| Supplemental Information | – | – | – | – |
| Interest Income | $796 | $1,570 | $252 | $22 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $174 | $1,520 | $5,507 | $2,301 |
| EBITDA | -$13,703 | -$32,482 | -$82,687 | -$57,684 |
| % Margin | – | -30,357% | -9,603.6% | -311.3% |